GlassScriptPhysician profile
Craig Alan Nicholson
NPI 1033223318
$21,419.22
in general payments reported to CMS, 2019-2025
32 companies · $365 in 2025
The $365 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,852 · 2020: $4,012 · 2021: $4,162 · 2022: $7,286 · 2023: $982 · 2024: $1,760 · 2025: $365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,127 · Travel and Lodging: $722 · Honoraria: $258.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,127.09 |
| Travel and Lodging | $722.25 |
| Honoraria | $257.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $11,681.21 | 2021-2024 | Axonics, Bulkamid |
| Boston Scientific Corporation | $6,038.62 | 2019-2022 | |
| Procept Biorobotics Corporation | $1,019.25 | 2024-2025 | Aquabeam System |
| Intuitive Surgical, INC. | $545.51 | 2019-2021 | |
| Janssen Biotech, INC. | $233.76 | 2019-2024 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $220.03 | 2023-2025 | Orgovyx, Gemtesa |
| Teleflex LLC | $201.21 | 2023-2025 | Urolift, Barrigel |
| Astellas Pharma US INC | $179.53 | 2019-2023 | Myrbetriq |
| C. R. Bard, INC. & Subsidiaries | $175.18 | 2023-2024 | Bard Urinary Drainage Bag |
| Accord Healthcare, INC. | $136.45 | 2022-2025 | |
| Olympus America INC. | $127.97 | 2023-2024 | Itind System |
| Medtronic USA, INC. | $125.00 | 2020 | |
| Comsort, INC | $100.00 | 2019 | |
| 180 Medical, INC. | $72.36 | 2023-2024 | |
| Karl Storz Endoscopy-America | $63.80 | 2024 | Hopkins |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Urogen Pharma, INC. | $56.35 | 2023-2025 | Jelmyto |
| Siemens Medical Solutions USA, INC. | $55.77 | 2020-2023 | |
| Pfizer INC. | $49.09 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $41.40 | 2023-2024 | Lynparza, Welireg, Keytruda |
| Ferring Pharmaceuticals INC. | $38.51 | 2024-2025 | Adstiladrin |
| Bayer Healthcare Pharmaceuticals INC. | $36.38 | 2023 | |
| Tolmar, INC. | $34.96 | 2023-2024 | |
| Srs Medical Systems, INC. | $34.20 | 2021 | |
| Progenics Pharmaceuticals, INC. | $24.47 | 2024 | |
| Blue Earth Diagnostics | $23.64 | 2024 | |
| Abbvie INC. | $23.27 | 2024 | |
| Sun Pharmaceutical Industries INC. | $21.99 | 2023 | Yonsa |
| Myriad Genetic Laboratories, INC. | $18.29 | 2023 | Prolaris |
| Photocure INC | $17.00 | 2024 | Cysview |
| Medtronic, INC. | $13.19 | 2024 | Interstim |
| Coloplast Corp | $10.83 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$657.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Craig Nicholson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.